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Recent decades have witnessed the revelation of expanding
roles of the vitamin D endocrine system beyond calcium and
phosphorus metabolism. Along with these non-calcemic or
non-classic actions of vitamin D are newly discovered
therapeutic actions of vitamin D analogs in a number of
pathological conditions, including kidney disease. The kidney
is the major organ involved in the synthesis of the hormonal
metabolite of vitamin D, and vitamin D deficiency is a
common feature of chronic kidney disease even in its early
stages. Experimental data suggest that vitamin D deficiency
may in turn accelerate the progression of kidney disease.
Low-calcemic vitamin D analogs have exhibited impressive
therapeutic effects in various kidney disease models, with
targets ranging from the NF-jB pathway to the
renin–angiotensin system. These recent studies demonstrate
that vitamin D analogs have potent renoprotective effects.
The emerging experimental and clinical evidence has
provided a solid foundation for the continuing exploration of
vitamin D analogs in prevention and intervention in kidney
disease.
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Chronic kidney disease (CKD) is a worldwide public health
problem affecting more than 50 million people. With the
growing global epidemic of metabolic syndrome and diabetes
in particular, the prevalence of CKD and kidney failure is
continuously rising. In the United States, the incidence and
prevalence of end-stage renal disease have doubled in the past
10 years and are expected to continue to rise steadily in the
future. The National Kidney Foundation-Kidney Disease
Outcomes Quality Initiative (NKF-KDOQI) estimates that
CKD affects 11% of the US population. Clinical care and
management of kidney disease are costly with poor out-
comes. New therapeutic strategies and methods for CKD
treatment are urgently needed. In recent years, vitamin D
deficiency has been recognized as a prominent feature of
CKD, and there is evidence to suggest that vitamin D
deficiency in turn accelerates the progression of kidney
disease. Recent studies have revealed an important renopro-
tective role that the vitamin D hormone and its analogs play
against renal injury, and impressive therapeutic efficacy has
been reported for low-calcemic vitamin D analogs in various
kidney disease models as well as in clinical trials. The
emerging experimental and clinical data point to a promising
future for vitamin D analogs as therapeutic agents for CKD.
VITAMIN D AND KIDNEY DISEASE
The majority of circulating vitamin D metabolites in humans
is initially synthesized as vitamin D3 in the skin from
7-dehydrocholesterol by UVB light radiation. Vitamin D3 is
converted to the active hormone 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] through two steps of hydroxylation reaction:
first in the liver catalyzed by 25-hydroxylase and then in the
kidney catalyzed by 1a-hydroxylase (the rate-limiting
reaction), and 1,25(OH)2D3 is further hydroxylated by the
broadly expressed 24-hydroxylase to start the catabolic
process.1 Because of the requirement of UV catalysis, vitamin
D status is highly influenced by factors such as sunlight
exposure, seasonal changes, geographic locations and skin
colors.1 25-hydroxyvitamin D3 (25OHD3), the first hydro-
xylation product from the liver, is the most abundant vitamin
D metabolite in the circulation and commonly used as the
indicator of vitamin D status in the body.
The activities of 1,25(OH)2D3 are mediated by the vitamin
D receptor (VDR), a member of the nuclear receptor
superfamily.2 The most well known function of the vitamin
D endocrine system is to maintain calcium and phosphorus
homoeostasis; however, studies in the past decades have
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unveiled a wide range of activities for vitamin D that extends
beyond the regulation of calcium and phosphorus metabo-
lism. These so-called non-calcemic activities include regula-
tion of renal and cardiovascular functions and modulation of
immune response.3,4 The molecular basis for the broad
functionalities of vitamin D is the expression of the VDR in
virtually all tissues in the body. Relevant examples of these
non-calcemic activities are regulation of the renin–angioten-
sin system (RAS) and the nuclear factor (NF)-kB pathway,5,6
two pathways involved in a broad range of pathological
processes. The RAS is a regulatory cascade with angiotensin
(Ang) II as the central effector. Ang II is generated by two
steps of enzymatic cleavage: the first step is the rate-limiting
step in which angiotensinogen is cleaved to Ang I by renin,
and Ang I is then converted to Ang II by angiotensin-
converting enzyme (ACE). Through binding to its G protein-
coupled receptors, Ang II exerts a broad range of physio-
logical and pathological actions, particularly in the
cardiovascular system and the kidney.7,8 NF-kB is a family
of transcription factors that functions as a master regulator of
immune response.9 NF-kB regulates a wide range of genes
involved in inflammation, proliferation and fibrogenesis and
is known to have a key role in kidney disease.10
The kidney has a key role in vitamin D metabolism. It not
only provides the enzymatic system for the synthesis of
1,25(OH)2D3,
1 but also is involved in the uptake of filtrated
25OHD3 from the urine in the form of vitamin D-binding
protein (DBP)-25OHD3 complex through megalin-mediated
endocytosis.11 Renal 1a-hydroxylase activity starts to decline
even in the early stages of CKD. Continued progression of
CKD leads to accumulation of phosphate in the serum, which
suppresses 1a-hydroxylase activity. Furthermore, proteinuria,
a hallmark of renal disease particularly in patients with
diabetic nephropathy, leads to loss of DBP-25OHD3 in the
urine and thus reduces the megalin-mediated uptake of
25OHD3. Therefore, it is not surprising that vitamin
D-deficiency, particularly 1,25(OH)2D3-deficiency, is com-
monly observed in patients with CKD even at the early stages
of the disease12 because of impaired renal functions.
Increasing evidence has demonstrated a correlation between
vitamin D-deficiency and progression of CKD, and plasma
vitamin D status is an independent inverse predictor of
disease progression and death in patients with CKD.13 Thus
vitamin D-deficiency may in fact accelerate the progression
of kidney disease.
THERAPEUTIC BENEFITS OF VITAMIN D AND ITS ANALOGS
IN CKD
In CKD, the decrease in 1,25(OH)2D3 levels coincides with
the increase in parathyroid hormone (PTH) levels. Secondary
hyperparathyroidism is a prominent problem for patients
with advanced stage CKD. The major consequence of
chronically elevated PTH is bone loss and fracture, due to
PTH stimulation of bone resorption. Another major
complication of CKD is cardiovascular disease with poorly
defined molecular causes. To suppress PTH, 1,25(OH)2D3
(calcitriol) and vitamin D analogs are the primary treatment
for secondary hyperparathyroidism. Currently the approved
vitamin D analogs for CKD include doxercalciferol
(1a-hydroxyvitamin D2), paricalcitol (1,25-dihydroxy-19-
nor-vitamin D2), and 22-oxacalcitriol (1,25-dihydroxy-22-
oxavitamin D3, for use in Japan). These analogs retain the
PTH-suppressing activity but have much less calcemic effects
than calcitriol.
Emerging evidence from a series of recent clinical studies
indicate that the therapeutic effects of vitamin D and vitamin
D analogs in CKD are beyond the control of hyperparathyr-
oidism and calcium and phosphorus metabolism. Vitamin D
and vitamin D analog therapy has shown multiple beneficial
effects in both hemodialysis14 and non-dialysis CKD
patients,15 leading to significant survival advantage for
patients receiving the therapy, and these therapeutic and
protective effects are independent of suppression of PTH. For
example, Teng et al.16 retrospectively analyzed the 2-year
mortality rate in a large cohort of chronic hemodialysis
patients in the United States who received or did not receive
calcitriol or vitamin D analogs, and found that the group of
patients who received the treatment had at least 20% survival
advantage over those who did not. The mortal benefits of
the vitamin D analogs paricalcitol and doxercalciferol are
greater than calcitriol.17,18 These clinical studies revealed an
association between vitamin D therapy and lower risk of
death and cardiovascular death. As the risk of death was
significantly lower at all levels of serum calcium, phosphorus
and PTH, the underlying protective mechanism likely
extends beyond the impact on PTH and mineral metabolism.
Now the mechanism underlying the survival advantage of
vitamin D therapy is a subject of intense investigations. Given
the pleiotropic nature of vitamin D activity, the survival
advantage that the therapy provides may be contributed by
effects on multiple targets. For example, vitamin D’s action
on the kidney, the heart, the vascular system and the immune
system, as well as on glucose metabolism and other key
physiological processes may all contribute to the survival
benefit.
RENOPROTECTIVE EFFECTS OF VITAMIN D ANALOGS
The VDR is highly expressed in the kidney; therefore, the
kidney is a major natural target organ of vitamin D actions.
Recent studies using a variety of experimental models,
including unilateral ureteral obstruction (UUO) model,
anti-thy-1 glomerulonephritis model, subtotally nephrecto-
mized model and diabetic nephropathy model, have clearly
established that vitamin D analogs have renoprotective effects
against renal injury. This conclusion is particularly solid and
credible as it is supported by data from different kidney
disease models, and these data indicate that vitamin D
analogs specifically target a few common pathways involved
in kidney disease progression. These include inhibition of
renal fibrosis, inflammation and development of proteinuria.
Interstitial fibrosis is a hallmark of chronic renal failure
and strongly correlated with deterioration of renal functions,
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regardless of the underlying disease. The most prominent
feature of fibrosis is the increased accumulation of extra-
cellular matrix (ECM) in the interstitial space. The UUO
model is a well-established model of tubulointerstitial fibrosis
of the kidney. Tan et al.19 showed that treatment of mice with
UUO with paricalcitol markedly attenuated tobulointerstitial
fibrosis. In the obstructive kidney, paricalcitol suppressed the
induction of ECM proteins including fibronectin and type I
and III collagens, as well as a-SMA, the marker for epithelial
to mesenchymal transition. Consistently, the pro-fibrotic
TGF-b pathway was also repressed by paricalcitol. On the
other hand, VDR-null genetic mutant mice developed more
severe interstitial fibrosis in the UUO model. Similarly, in rats
with anti-thy-1.1 antibody-induced glomerulonephritis,
treatment with 22-oxacalcitriol ameliorated glomerulosclero-
sis, with reduction of type I and type IV collagens and
a-SMA.20
The subtotally nephrectomized model recapitulates renal
insufficiency seen in advanced stage CKD. The pathophysiol-
ogy of this model is characterized by progressive glomerular
and tubulointerstitial damage, glomerular hypertension and
proteinuria, in which the activation of the RAS has a pivotal
role. A series of studies have demonstrated renoprotective
effects of vitamin D analogs in this experimental model.
Earlier reports showed that administration of 1,25(OH)2D3
reduced glomerulosclerosis and albuminuria and prevented
podocyte injury in nephrectomized rats, and these effects
were independent of PTH.21,22 Recently Freundlich et al.23
demonstrated that treatment of rats with 5/6 nephrectomy
with paricalcitol suppressed the activation of the local
RAS in the kidney, significantly attenuated glomerular and
tubulointerstitial damage and reduced high blood pressure
and proteinuria, suggesting the importance of blockade o
f the RAS in prevention of the deterioration of renal
function. Considering the key role of the RAS in renal
injury in this model, Mizobuchi et al.24 used a combi-
nation of ACE inhibitor and paricalcitol to treat 5/6
nephrectomized rats. They found that this combination
reduced progression of renal insufficiency more effectively
than paricalcitol alone, with reduction of glomerulosclerosis
and suppression of TGF-b and MCP-1 expression. This
study, however, did not determine the status of the local RAS
in the kidney.
THERAPEUTIC EFFECTS ON DIABETIC NEPHROPATHY
Diabetes mellitus is a rapidly growing epidemic in the global
scale. In the United States 23.6 million people or 7.8% of the
population had diabetes in 2007. Diabetes is by far the
leading cause of CKD, accounting for 44% of new cases of
end-stage renal disease in 2005. Diabetic nephropathy is the
most common long-term renal complication of both type 1
and type 2 diabetic mellitus. Hyperglycemia is the major
determinant for the development of diabetic nephropathy.
High glucose activates a number of pathological pathways in
the kidney, including the RAS and NF-kB, which lead to renal
injury.
Recent studies have provided evidence that the VDR has a
renoprotective role against the development of diabetic
nephropathy. Zhang et al.25 reported that in a diabetic state
VDR-null mutant mice developed more severe renal injury
than wild-type mice. When VDR knockout and wild-type
mice were induced to diabetes with streptozotocin, VDR-null
mice showed earlier and more severe albuminuria, accom-
panied by more extensive damage of the glomerular filtration
barrier and podocytes, even though hyperglycemia was
similar in both genotypes. The mutant mice also exhibited
a higher degree of glomerulosclerosis with more ECM
protein production. The investigators demonstrated that
the underlying mechanism for the more severe renal injury in
diabetic VDR knockout mice is the more robust activation of
the local RAS in the kidney, with higher induction of renin,
angiotensinogen (AGT) and AT1 receptor, suggesting that
vitamin D attenuates hyperglycemia-induced renal injury by
suppressing the RAS. Other mechanisms, such as suppression
of inflammation, may also involve in the renoprotective
actions of vitamin D.
It is well established that the local RAS in the kidney is the
major mediator of renal damage in diabetes.26 Kidney cells
have the capacity to synthesize all components of the RAS,
which are highly inducible by hyperglycemia. In diabetes the
intrarenal interstitial Ang II levels can reach as much as 1000
times higher than in the plasma. Currently the first line of
treatment for diabetic nephropathy is the inhibition of the
RAS. ACE inhibitors (ACEI), Ang II type 1 receptor blockers
(ARB) and the renin inhibitor aliskiren have been shown to
reduce the progression of diabetic nephropathy in a number
of large clinical trials;27–31 however, the growing number of
patients with CKD attest that these therapies are insufficient
and ineffective to halt the epidemic of kidney disease. One
problem that reduces the efficacy of these RAS inhibitors is
the compensatory increase of renin synthesis caused by the
disruption of the feedback inhibition loop by the inhibitors
themselves.32 (Figure 1). Renin build-up in the plasma and
tissue interstitial space stimulates the conversion of Ang I and
ultimately Ang II. Ang II accumulation eventually limits the
efficacy of RAS inhibition and may explain why the current
RAS inhibitors are only suboptimal clinically. Zhang et al.33
have demonstrated that blocking the compensatory increase
of renin expression with vitamin D analogs dramatically
increases the therapeutic efficacy of RAS inhibition in
experimental diabetes models (Figure 1).
In this recent study Zhang et al.25 treated streptozotocin-
induced diabetic mice with a combination of losartan (an
AT1 ARB) and paricalcitol or single compound alone, and
found that the combination strategy produced synergistic
therapeutic effects much better than single treatment with
losartan or paricalcitol. Although losartan or paricalcitol
alone moderately ameliorated kidney injury, the combination
completely prevented albuminuria, restored glomerular filtra-
tion barrier structure, reduced glomerulosclerosis and blocked
macrophage infiltration. These were accompanied by suppres-
sion of ECM proteins, pro-fibrotic and pro-inflammatory
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cytokines (such as TGF-b, MCP-1, CTGF, and VEGF) and
reversal of the decline of slit diaphragm proteins. The
molecular basis underlying the synergistic effect of the
combination therapy, at least in large part, is the blockade of
the compensatory renin increase and Ang II accumulation
within the kidney, which are induced by hyperglycemia and
losartan itself. Similar synergistic effects have also been
observed with losartan and doxercalciferol combination in
experimental diabetes models by the same group. As the
treatments have little impact on the hyperglycemic status of the
diabetic animals, the anti-proteinuric and anti-sclerotic effects
of the therapy are largely kidney-specific. These preclinical
investigations have important implications for the therapeutic
treatment of diabetic kidney disease in humans.
A number of clinical studies have confirmed the potent
anti-proteinuric effects of vitamin D and vitamin D analogs.
In a large cohort cross-sectional analysis of data from the
Third National Health and Nutrition Examination Survey
(NHANES III), vitamin D-insufficiency was found to be
associated with increased prevalence of albuminuria,34
suggesting that vitamin D has an intrinsic anti-proteinuric
property. The anti-proteinuric activity of vitamin D analogs
was reported in a retrospective analysis of patients with CKD
conducted by Agarwal et al.35 In that study the beneficial
effect of paricalcitol was seen even in subjects already treated
with ACEI or ARB, indicating that the vitamin D analog has
additive or synergistic effects with ACEI/ARB in reducing
proteinuria. In a recent randomized double-blind pilot trial
with 24 patients with stage 2–3 CKD, Alborzi et al.36 reported
that paricalcitol treatment for one month significantly
reduced albuminuria and inflammation status in the drug-
treated subjects, and these effects were independent of its
effects on hemodynamics and PTH suppression. The anti-
albuminuric effect of vitamin D analogs is of particular
significance, as albuminuria is a major risk factor for
progressive renal function decline and though to be the first
step in an inevitable progression to proteinuria and renal
failure. Thus reduction of albuminuria is a major target for
renoprotective therapy.
MECHANISMS OF RENOPROTECTION
What is the molecular mechanism underlying the renoprotec-
tive actions of vitamin D analogs? The data from experimental
and clinical studies published in recent years suggest that
vitamin D analogs protect the kidney by targeting two major
pathways that promote renal damage and progression of kidney
disease: the local RAS and the NF-kB pathway (Figure 2). The
hallmarks of kidney disease are proteinuria, glomeruloslcerosis
and tubulointerstitial fibrosis, and these two pathways are fully
involved in these pathogenic processes.
Many pathological factors such as hyperglycemia, renal
insufficiency and vitamin D-deficiency can activate the local
RAS in the kidney, leading to increased local production of

















Figure 2 |Mechanism of renoprotection by vitamin D and its
analogs. The renin–angiotensin system and the NF-kB activation
pathway have major roles in causing renal damage. They promote
the production of pro-fibrotic and pro-inflammatory factors,
increase oxidative stress, and damage podocytes. Ang II also
exerts hemodynamic effects on glomeruli to induce proteinuria.
Ang II can activate NF-kB, which in turn stimulates
angiotensinogen expression, forming a vicious circle. Vitamin D
and its analogs inhibit renin expression and suppress NF-kB
activation by disrupting its DNA binding. Vitamin D and its
analogs also suppress angiotensinogen expression by targeting
















Figure 1 |Mechanism underlying the compensatory increase
of renin production and its inhibition by vitamin D and its
analogs. Renin, synthesized by the renin gene, catalyzes the
conversion of angiotensinogen to angiotensin (Ang) I, which is
further cleaved to Ang II by angiotensin-converting enzyme (ACE).
Ang II activates the angiotensin type I (AT1) receptor to suppress
renin gene expression. This negative feedback loop is required to
maintain the homeostasis of the renin-angiotensin system (RAS).
When the system is inhibited with renin enzymatic inhibitor, ACE
inhibitor (ACEI), or AT1 receptor blocker (ARB), this feedback loop
is disrupted, leading to overexpression of renin. The
compensatory renin overproduction then increases Ang I
conversion, which ultimately leads to Ang II increase, thus
reducing the efficacy of inhibition of the RAS. On the other hand,
increased renin can also activate the (pro)renin receptor
independent of Ang II to cause organ damage. As vitamin D and
its analogs suppress renin gene expression, when any of the three
classes of RAS inhibitors is combined with a vitamin D analog,
vitamin D analog will block the compensatory renin expression
and thus enhance the efficacy of RAS inhibition. That is the
molecular basis for synergism between vitamin D analogs and
classic RAS inhibitors.
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insufficiency, loss of nephrons causes hyperfiltration and
glomerular capillary hypertension, which can stimulate the
local RAS, and reduction in calcitriol production also activate
the local RAS. Ang II has a broad range of pathological
activities. For example, it induces vasoconstriction and
oxidative stress, and induces cell proliferation, inflammation
and fibrogenesis. In the kidney Ang II exerts multiple actions
that promote the progression of renal injury and ultimately
renal failure.7,8 These actions include increasing glomerular
capillary pressure, inducing pro-fibrotic and pro-inflamma-
tory cytokines and growth factors (such as TGF-b and
MCP-1), promoting immune cell infiltration, stimulating cell
proliferation and hypertrophy, upregulating ECM synthesis
and damaging podocytes (Figure 2). For example, transgenic
rats overexpressing AT1 receptor in podocytes developed
marked albuminuria and glomerulosclerosis,37 reaffirming
the destructive role of intrarenal Ang II.
NF-kB is known to play important roles in renal diseases
by promoting inflammation and fibrogenesis10 (Figure 2).
Renal inflammation is common in patients with a variety of
kidney diseases. The NF-kB activation pathway is a master
regulator of immune response and involved in the regulation
of inflammatory cytokines and chemokines (such as MCP-1,
PAI-1 and TNFa) that are involved in development of kidney
disease. For example, MCP-1 promotes macrophage infiltra-
tion in the kidney, a problem seen in a number of kidney
diseases. Macrophages release many factors that promote
kidney disease progression. Bacterial infection, LPS, and high
glucose are known to activate NF-kB in kidney cells. NF-kB
activation has been reported in patients with diabetic
nephropathy. Interestingly, Ang II activates NF-kB, whereas
NF-kB mediates high glucose-induced AGT expression in
kidney cells.38 This vicious circle promotes the local
accumulation of Ang II in diabetic nephropathy (Figure 2).
The evidence that supports vitamin D regulation of the
RAS and NF-kB is abundant and strong. Inhibition of the
RAS by 1,25(OH)2D3 has been well established.
5 The
molecular mechanism underlying this negative regulation is
that 1,25(OH)2D3 suppresses renin gene transcription by
disrupting the cAMP-signaling pathway, a major regulatory
pathway involved in renin biosynthesis.39 Null mutant mice
lacking VDR or 1a-hydroxylase developed hyper-
reninemia,40,41 with drastic upregulation of renin expression
in the kidney and other tissues. 1,25(OH)2D3 and vitamin D
analogs have been shown to inhibit renin expression in
animals.40,42,43 Targeted expression of human VDR in the
juxtaglomerular cells in transgenic mice led to suppression of
renin expression independent of calcium and PTH.44
Numerous studies have demonstrated the suppression of
NF-kB activation by vitamin D, partly through disruption of
NF-kB DNA binding. Fibroblasts lacking VDR display
intrinsic activation of NF-kB.6 Paricalcitol was shown to
reduce renal inflammation by blocking NF-kB activity in
UUO mice.45 Consistently, plasma vitamin D status was
found to be inversely associated with increased renal
inflammation in patients with a variety of kidney diseases.46
1,25(OH)2D3 inhibits high glucose-induced expression of
MCP-1 and AGT by blocking the activation of NF-kB,38,47
and importantly, the latter helps break the vicious circle of
RAS and NF-kB interaction in kidney disease (Figure 2).
CONCLUSION
Growing evidence from a number of experimental models
and clinical studies has presented a very strong case for a
renoprotective role for vitamin D and vitamin D analogs in
the development of kidney disease. The molecular mechan-
ism for the renoprotection has been at least partially defined.
These preclinical and clinical data have laid down a solid
foundation for more and large randomized controlled clinical
trials to test the therapeutic effects of vitamin D analogs and
calcitriol in various kidney diseases. Given the increasing
prevalence of CKD around the world, new and more effective
approaches for therapeutic intervention of CKD are particu-
larly needed. At present, there are quite a number of ongoing
clinical trials in the category of vitamin D analogs and kidney
disease, and more trials are expected in the future. It is
interesting to see whether these trials will fulfill some of the
promises of vitamin D.
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